NeuroPace develops and offers the RNS System, an FDA-approved device for the personalized treatment of drug-resistant focal epilepsy, providing insights into seizure trends and triggers.

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

COM:NEUROPACE

NeuroPace

Last Close

9.00

22/11 21:00

Market Cap

197.64M

Beta: -

Volume Today

66.64K

Avg: -

locale

market

industry

website

ipo date

peer of

Metrics